Abstract:Neuropharmacological effects of psychedelics have profound cognitive, emotional, and social effects that inspired the development of cultures and religions worldwide. Findings that psychedelics objectively and reliably produce mystical experiences press the question of the neuropharmacological mechanisms by which these highly significant experiences are produced by exogenous neurotransmitter analogs. Humans have a long evolutionary relationship with psychedelics, a consequence of psychedelics' selective effects for human cognitive abilities, exemplified in the information rich visionary experiences. Objective evidence that psychedelics produce classic mystical experiences, coupled with the finding that hallucinatory experiences can be induced by many non-drug mechanisms, illustrates the need for a common model of visionary effects. Several models implicate disturbances of normal regulatory processes in the brain as the underlying mechanisms responsible for the similarities of visionary experiences produced by psychedelic and other methods for altering consciousness. Similarities in psychedelic-induced visionary experiences and those produced by practices such as meditation and hypnosis and pathological conditions such as epilepsy indicate the need for a general model explaining visionary experiences. Common mechanisms underlying diverse alterations of consciousness involve the disruption of normal functions of the prefrontal cortex and default mode network (DMN). This interruption of ordinary control mechanisms allows for the release of thalamic and other lower brain discharges that stimulate a visual information representation system and release the effects of innate cognitive functions and operators. Converging forms of evidence support the hypothesis that the source of psychedelic experiences involves the emergence of these innate cognitive processes of lower brain systems, with visionary experiences resulting from the activation of innate processes based in the mirror neuron system (MNS).

The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

Psychedelics and Neural Plasticity: Therapeutic Implications

Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

Unifying Theories of Psychedelic Drug Effects

Psychedelic research at a crossroads

The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology

Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain

Making Sense of Psychedelics in the CNS

Psychedelics and Other Psychoplastogens for Treating Mental Illness

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

Robust Methods For Quantifying Neuronal Morphology And Molecular Signaling Reveal That Psychedelics Do Not Induce Neuroplasticity

Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

A dual-receptor model of serotonergic psychedelics

CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality

[Therapeutic applications of classical serotonergic psyche-delics: neurobiological mechanisms and neural networks]

Classical psychedelics' action on brain monoaminergic systems